目的研究普伐他汀在大鼠小肠吸收及肝脏分布特征。
OBJECTIVE To study the intestinal absorption and liver distribution characters of pravastatin in rats.
目的：比较氟伐他汀和普伐他汀调整血脂的临床效果。
Objective: To compare the lipid - regulating effects of fluvastatin and pravastatin.
结论：普伐他汀不仅能明显降低血脂，而且能改善患者的血液流变性。
CONCLUSIONS The pravastatin not only can regulate blood lipid, but also can improve hemorheology in patients with hyperlipidemia.
应用普伐他汀治疗后，冠心病患者的斑块积分和内中膜厚度均有所减小；
The area of plaques and intima media thickness in CHD group were thinner after treatment of pravastatin.
目的研究普伐他汀对冠心病的微循环及血液流变性影响，探讨其降脂外作用。
Objective Investigation on the changes of the microcirculation and blood rheology after using pravastatin and exploration of the effects other than lowering the level of blood lipid.
调脂增寿汤与普伐他汀片均可有效降低动脉硬化指数及非高密度脂蛋白胆固醇；
The level of HDLc were significantly increased and the levels of ApoBioo and Hey were significantly decreased in Tiaozhi Zengshou Decoction group.
结论：普伐他汀促进动脉粥样硬化斑块消退的早期效益是由于对血小板功能的良性影响而产生。
Conclusion: the early benefit of pravastatin in enhancing atherosclerosis regression was partly due to the improvement of platelet function.
方法观察10 2例冠心病患者普伐他汀治疗前后血脂及血液流变学、微循环检测结果并作对比分析。
Method The changes of blood lipid microcirculation and blood rheology before and after the pravastatin administration were observed and analysed in 102 cases of coronary heart disease.
结论普伐他汀可改善代谢综合征患者的血脂紊乱、高血压及微量白蛋白尿，可安全地应用于代谢综合征患者。
Conclusion Pravastatin can be safely used for treating metabolic syndrome because it can ameliorate the lipid disturbance, hypertension and microalbuminuria.
结论普伐他汀降脂疗效显著，可减轻动脉粥样硬化的程度，改善血管内皮功能，使心绞痛治疗疗效明显提高。
Conclusion Pravastatin can decrease blood lipid dramatically, relieve atherosclerosis, improve endothelium function and enhance the total treatment efficiency rate for angina.
结论普伐他汀能够阻止或延缓糖尿病视网膜形态改变；普伐他汀能够减弱糖尿病大鼠视网膜组织中MCP - 1的表达。
Conclusion pravastatin could control and delay the morphological changes of diabetic retinopathy, and pravastatin could decreased the expression of MCP-1 in diabetic retina.
结论：普伐他汀不能抑制肝细胞PAI-1的分泌。羟甲基戊二酰辅酶A还原酶的抑制与PAI- 1分泌可能没有关系。
Conclusion:Pravastatin can not inhibit the secretion of PAI 1 in hepatic cells and the inhibition of hydroxymethylglutaryl coenzyme A reductase may not be related to the secretion of PAI 1.
结果：黄芪当归合剂不仅有普伐他汀的降低胆固醇和甘油三酯的作用，还能降低低密度脂蛋白和载脂蛋白B（100）（P＜0．05）。
Results: AAM could not only reduce the serum levels of total cholesterol and triglyceride as pravachol did, but also could lower levels of low density lipoprotein and apolipoprotein B100(P<0. 05).
结果：黄芪当归合剂不仅有普伐他汀的降低胆固醇和甘油三酯的作用，还能降低低密度脂蛋白和载脂蛋白B（100）（P＜0．05）。
Results: AAM could not only reduce the serum levels of total cholesterol and triglyceride as pravachol did, but also could lower levels of low density lipoprotein and apolipoprotein B100(P<0. 05).
应用推荐